Bladder Cancer – Robert Figlin, MD, and Arjun Balar, MD, discuss clinical progress in bladder cancer

Sunday February 28, 2021

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Arjun Balar, MD, Director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discuss clinical progress in bladder cancer

Prostate Cancer – Robert Figlin, MD, and Neeraj Agarwal, MD, discuss clinical progress in prostate cancer

Monday February 22, 2021

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Neeraj Agarwal, MD, Professor of Medicine, Huntsman Cancer Institute, Presidential Endowed Chair of Cancer Research , Co-Leader, HCI Experimental Therapeutics Program, Director, Center of Investigational Therapeutics, Director, Genitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, discuss clinical progress in prostate cancer

Renal Cell Carcinoma (RCC) – Robert Figlin, MD and Toni Choueiri, MD, discuss clinical progress in renal cell carcinoma (RCC)

Monday February 22, 2021

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Toni Choueiri, MD, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, discuss clinical progress in renal cell carcinoma (RCC)

Breast Cancer – Robert Figlin, MD, and Adam Brufsky, MD, PhD, discuss clinical highlights from SABCS 2020

Tuesday January 12, 2021

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Adam Brufsky, MD, PhD, Professor of Medicine, Associate Division Chief for the Division of Hematology/Oncology, UPMC, discuss clinical highlights from SABCS 2020

Chronic Lymphocytic Leukemia (CLL) – Robert Figlin, MD, and Mazyar Shadman, MD, MPH, discuss clinical highlights from ASH 2020

Monday January 11, 2021

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Mazyar Shadman, MD, MPH, Associate Professor, Clinical Research Division Fred Hutchinson Cancer Research Center, discuss clinical highlights in the treatment of CLL from ASH 2020

Renal Cell Carcinoma (RCC) – Bradley McGregor, MD, and Robert Figlin, MD, discuss clinical highlights from ESMO 2020

Monday October 26, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley McGregor, MD, Clinical Director, Lank Center for Genitourinary Oncology, Professor of Medicine, Harvard Medical School, discuss Checkmate 9ER and other I-O studies as they pertain to the management of RCC patients

Non Small Cell Lung Cancer – Victoria Villaflor, MD, and Robert Figlin, MD, discuss unresectable stage III NSCLC

Wednesday October 21, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Victoria Villaflor, MD, Clinical Professor, Director Head and Neck Oncology at City of Hope, discuss unresectable stage III Non Small Cell Lung Cancer (www.azioinpractice.com)

Gastric/GE Junction Cancer – Geoffrey Ku, MD, and Robert Figlin, MD, discuss recent clinical developments in gastric and esophageal cancer

Friday October 16, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Geoffrey Ku, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discuss recent clinical developments in gastric and esophageal cancer

Breast Cancer – Sara Hurvitz, MD, and Robert Figlin, MD, discuss recent clinical developments in early stage and late stage breast cancer

Friday July 17, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Sara Hurvitz, MD, Associate Professor of Medicine, Geffen School of Medicine, UCLA, Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit, discuss breast cancer patient types, challenges, and treatment advances.

Adjuvant Lung Cancer – Roy Herbst, MD, and Robert Figlin, MD, discuss the recent ASCO20 plenary presentation of the ADAURA study investigating the use of Tagrisso (osimertinib) in stage I-III EGFR+ NSCLC patients

Thursday June 25, 2020

Roy Herbst, MD, and Robert Figlin, MD, discuss the implications of the ADAURA study investigating the use of Tagrisso (osimertinib) in stage I-III EGFR+ NSCLC patients